Cargando…

Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors

Gastric cancer (GC) is the one of the most prevalent cancers and one of the leading causes of cancer-induced deaths. Previously, we found that the expression of purinergic P2Y(2) receptor (P2Y(2)R) is increased in GC samples as compared to adjacent healthy mucosa taken from GC-diagnosed patients. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Hevia, María José, Castro, Patricio, Pinto, Katherine, Reyna-Jeldes, Mauricio, Rodríguez-Tirado, Felipe, Robles-Planells, Claudia, Ramírez-Rivera, Sebastián, Madariaga, Juan Andrés, Gutierrez, Felipe, López, Javier, Barra, Marcelo, De la Fuente-Ortega, Erwin, Bernal, Giuliano, Coddou, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584115/
https://www.ncbi.nlm.nih.gov/pubmed/31249523
http://dx.doi.org/10.3389/fphar.2019.00612
_version_ 1783428477254369280
author Hevia, María José
Castro, Patricio
Pinto, Katherine
Reyna-Jeldes, Mauricio
Rodríguez-Tirado, Felipe
Robles-Planells, Claudia
Ramírez-Rivera, Sebastián
Madariaga, Juan Andrés
Gutierrez, Felipe
López, Javier
Barra, Marcelo
De la Fuente-Ortega, Erwin
Bernal, Giuliano
Coddou, Claudio
author_facet Hevia, María José
Castro, Patricio
Pinto, Katherine
Reyna-Jeldes, Mauricio
Rodríguez-Tirado, Felipe
Robles-Planells, Claudia
Ramírez-Rivera, Sebastián
Madariaga, Juan Andrés
Gutierrez, Felipe
López, Javier
Barra, Marcelo
De la Fuente-Ortega, Erwin
Bernal, Giuliano
Coddou, Claudio
author_sort Hevia, María José
collection PubMed
description Gastric cancer (GC) is the one of the most prevalent cancers and one of the leading causes of cancer-induced deaths. Previously, we found that the expression of purinergic P2Y(2) receptor (P2Y(2)R) is increased in GC samples as compared to adjacent healthy mucosa taken from GC-diagnosed patients. In this work, we studied in detail purinergic signaling in the gastric adenocarcinoma-derived cell lines: AGS, MKN-45, and MKN-74, and compared them to a nontumoral epithelial cell line: GES-1. In GC-derived cells, we detected the expression of several purinergic receptors, and found important differences as compared to GES-1 cells. Functional studies revealed a strong contribution of P2Y(2)Rs in intracellular calcium increases, elicited by adenosine-triphosphate (ATP), uridine-triphosphate (UTP), and the P2Y(2)R agonist MRS2768. Responses were preserved in the absence of extracellular calcium and inhibited by P2Y(2)R antagonists. In GES-1 cells, ATP and UTP induced similar responses and the combination of P2X and P2Y receptor antagonists was able to block them. Proliferation studies showed that ATP regulates AGS and MKN-74 cells in a biphasic manner, increasing cell proliferation at 10–100 μM, but inhibiting at 300 μM ATP. On the other hand, 1–300 μM UTP, a P2Y(2)R agonist, increased concentration-dependent cell proliferation. The effects of UTP and ATP were prevented by both wide-range and specific purinergic antagonists. In contrast, in GES-1 cells ATP only decreased cell proliferation in a concentration-dependent manner, and UTP had no effect. Notably, the isolated application of purinergic antagonists was sufficient to change the basal proliferation of AGS cells, indicating that nucleotides released by the cells can act as paracrine/autocrine signals. Finally, in tumor-derived biopsies, we found an increase of P2Y(2)R and a decrease in P2X4R expression; however, we found high variability between seven different biopsies and their respective adjacent healthy gastric mucosa. Even so, we found a correlation between the expression levels of P2Y(2)R and P2X4R and survival rates of GC patients. Taken together, these results demonstrate the involvement of different purinergic receptors and signaling in GC, and the pattern of expression changes in tumoral cells, and this change likely directs ATP and nucleotide signaling from antiproliferative effects in healthy tissues to proliferative effects in cancer.
format Online
Article
Text
id pubmed-6584115
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65841152019-06-27 Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors Hevia, María José Castro, Patricio Pinto, Katherine Reyna-Jeldes, Mauricio Rodríguez-Tirado, Felipe Robles-Planells, Claudia Ramírez-Rivera, Sebastián Madariaga, Juan Andrés Gutierrez, Felipe López, Javier Barra, Marcelo De la Fuente-Ortega, Erwin Bernal, Giuliano Coddou, Claudio Front Pharmacol Pharmacology Gastric cancer (GC) is the one of the most prevalent cancers and one of the leading causes of cancer-induced deaths. Previously, we found that the expression of purinergic P2Y(2) receptor (P2Y(2)R) is increased in GC samples as compared to adjacent healthy mucosa taken from GC-diagnosed patients. In this work, we studied in detail purinergic signaling in the gastric adenocarcinoma-derived cell lines: AGS, MKN-45, and MKN-74, and compared them to a nontumoral epithelial cell line: GES-1. In GC-derived cells, we detected the expression of several purinergic receptors, and found important differences as compared to GES-1 cells. Functional studies revealed a strong contribution of P2Y(2)Rs in intracellular calcium increases, elicited by adenosine-triphosphate (ATP), uridine-triphosphate (UTP), and the P2Y(2)R agonist MRS2768. Responses were preserved in the absence of extracellular calcium and inhibited by P2Y(2)R antagonists. In GES-1 cells, ATP and UTP induced similar responses and the combination of P2X and P2Y receptor antagonists was able to block them. Proliferation studies showed that ATP regulates AGS and MKN-74 cells in a biphasic manner, increasing cell proliferation at 10–100 μM, but inhibiting at 300 μM ATP. On the other hand, 1–300 μM UTP, a P2Y(2)R agonist, increased concentration-dependent cell proliferation. The effects of UTP and ATP were prevented by both wide-range and specific purinergic antagonists. In contrast, in GES-1 cells ATP only decreased cell proliferation in a concentration-dependent manner, and UTP had no effect. Notably, the isolated application of purinergic antagonists was sufficient to change the basal proliferation of AGS cells, indicating that nucleotides released by the cells can act as paracrine/autocrine signals. Finally, in tumor-derived biopsies, we found an increase of P2Y(2)R and a decrease in P2X4R expression; however, we found high variability between seven different biopsies and their respective adjacent healthy gastric mucosa. Even so, we found a correlation between the expression levels of P2Y(2)R and P2X4R and survival rates of GC patients. Taken together, these results demonstrate the involvement of different purinergic receptors and signaling in GC, and the pattern of expression changes in tumoral cells, and this change likely directs ATP and nucleotide signaling from antiproliferative effects in healthy tissues to proliferative effects in cancer. Frontiers Media S.A. 2019-06-13 /pmc/articles/PMC6584115/ /pubmed/31249523 http://dx.doi.org/10.3389/fphar.2019.00612 Text en Copyright © 2019 Hevia, Castro, Pinto, Reyna-Jeldes, Rodríguez-Tirado, Robles-Planells, Ramírez-Rivera, Madariaga, Gutierrez, López, Barra, De la Fuente-Ortega, Bernal and Coddou http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hevia, María José
Castro, Patricio
Pinto, Katherine
Reyna-Jeldes, Mauricio
Rodríguez-Tirado, Felipe
Robles-Planells, Claudia
Ramírez-Rivera, Sebastián
Madariaga, Juan Andrés
Gutierrez, Felipe
López, Javier
Barra, Marcelo
De la Fuente-Ortega, Erwin
Bernal, Giuliano
Coddou, Claudio
Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title_full Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title_fullStr Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title_full_unstemmed Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title_short Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors
title_sort differential effects of purinergic signaling in gastric cancer-derived cells through p2y and p2x receptors
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584115/
https://www.ncbi.nlm.nih.gov/pubmed/31249523
http://dx.doi.org/10.3389/fphar.2019.00612
work_keys_str_mv AT heviamariajose differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT castropatricio differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT pintokatherine differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT reynajeldesmauricio differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT rodrigueztiradofelipe differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT roblesplanellsclaudia differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT ramirezriverasebastian differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT madariagajuanandres differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT gutierrezfelipe differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT lopezjavier differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT barramarcelo differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT delafuenteortegaerwin differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT bernalgiuliano differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors
AT coddouclaudio differentialeffectsofpurinergicsignalingingastriccancerderivedcellsthroughp2yandp2xreceptors